Key Takeaways
- • Sam Altman, CEO of OpenAI, secured a $75 million investment from the University of Michigan's $17.9 billion endowment for Hydrazine Capital's fourth fund, launched in March 2023, discovered by Fortune via Freedom of Information Act request.
- • The University of Michigan endowment is the sole outside investor in Hydrazine IV, marking the institution's second investment in Altman's venture firm and extending its existing portfolio that includes direct OpenAI investments and stakes in OpenAI's corporate venture fund.
- • The investment confirms that Altman's personal venture capital firm operates with institutional capital beyond his own funds or those of close associates, establishing Hydrazine as a vehicle managing third-party institutional allocations.
- • OpenAI stated that Altman "is fully focused on his role as CEO of OpenAI and spends only a small fraction of his time investing," addressing potential conflict-of-interest concerns regarding his dual roles.
- • The fund's exact size, investment thesis, and specific focus areas remain undisclosed; Hydrazine, Altman, OpenAI, and the University of Michigan declined to provide additional details beyond the confirmed $75 million commitment.
Summary
Sam Altman, the CEO of OpenAI, launched Hydrazine Capital's fourth investment fund in March 2023 and secured a $75 million commitment from the University of Michigan's endowment—one of the largest university investment portfolios at $17.9 billion. The investment was uncovered by Fortune through a Freedom of Information Act request and represents a significant institutional validation of Altman's venture capital operations outside his primary role at OpenAI.
The University of Michigan endowment serves as the exclusive outside investor in Hydrazine IV, according to Dan Feder, senior managing director of investments at the university's endowment office. Feder characterized the relationship as part of a "longstanding relationship with Sam and Hydrazine IV," noting that this commitment represents an extension of the institution's existing investment strategies. The investment marks the second time the University of Michigan endowment has committed capital to Altman's venture firm, signaling sustained institutional confidence in his investment acumen.
The arrangement is noteworthy for two critical reasons, according to Fortune's reporting. First, it provides the first public confirmation that Altman's personal venture capital firm manages institutional capital beyond his own or that of his immediate circle—a material distinction that elevates Hydrazine's status from a founder-backed vehicle to a professionally managed institutional fund. Second, the disclosure demonstrates that Altman has been actively fundraising for external ventures concurrent with his role as CEO of one of the world's most prominent artificial intelligence companies, particularly during a period when OpenAI's profile was rapidly ascending following ChatGPT's launch.
The University of Michigan endowment's portfolio connection to Altman extends beyond Hydrazine IV; the institution has made direct investments in OpenAI itself and holds positions in OpenAI's corporate venture fund, indicating a multi-layered institutional relationship. However, specific details regarding Hydrazine IV's fund size, investment focus, sector concentration, and return expectations remain confidential. When requested for additional disclosures, Hydrazine Capital, Altman, and OpenAI declined to comment. An OpenAI spokesperson addressed potential governance concerns by stating that Altman "is fully focused on his role as CEO of OpenAI and spends only a small fraction of his time investing," positioning his venture activities as a minor component of his overall time allocation.
The University of Michigan endowment serves as the exclusive outside investor in Hydrazine IV, according to Dan Feder, senior managing director of investments at the university's endowment office. Feder characterized the relationship as part of a "longstanding relationship with Sam and Hydrazine IV," noting that this commitment represents an extension of the institution's existing investment strategies. The investment marks the second time the University of Michigan endowment has committed capital to Altman's venture firm, signaling sustained institutional confidence in his investment acumen.
The arrangement is noteworthy for two critical reasons, according to Fortune's reporting. First, it provides the first public confirmation that Altman's personal venture capital firm manages institutional capital beyond his own or that of his immediate circle—a material distinction that elevates Hydrazine's status from a founder-backed vehicle to a professionally managed institutional fund. Second, the disclosure demonstrates that Altman has been actively fundraising for external ventures concurrent with his role as CEO of one of the world's most prominent artificial intelligence companies, particularly during a period when OpenAI's profile was rapidly ascending following ChatGPT's launch.
The University of Michigan endowment's portfolio connection to Altman extends beyond Hydrazine IV; the institution has made direct investments in OpenAI itself and holds positions in OpenAI's corporate venture fund, indicating a multi-layered institutional relationship. However, specific details regarding Hydrazine IV's fund size, investment focus, sector concentration, and return expectations remain confidential. When requested for additional disclosures, Hydrazine Capital, Altman, and OpenAI declined to comment. An OpenAI spokesperson addressed potential governance concerns by stating that Altman "is fully focused on his role as CEO of OpenAI and spends only a small fraction of his time investing," positioning his venture activities as a minor component of his overall time allocation.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.